KRAS Kickers founded by a lung cancer patient as a patient empowerment group to understand what to do about plus what it means to have a KRAS positive cancer
We learn what we need to know from the KRAS world experts through webinars,. We connect with other patients and care partners in virtual support groups plus our private Facebook community.
11/14/2025
KRAS Kickers Cancer Connect 2026 registration is OPEN!
On February 19-20, in San Francisco, join in a community of people who get it — patients, care partners, premier researchers, and advocates coming together to learn, connect, and kick KRAS as a team.
You don’t have to navigate KRAS alone. At the KRAS Cancer Connect, we are bringing together our community for real conversations, expert insights, and the support every patient and care partner deserves! 💙
🎙️ New Episode: A Conversation with a KRAS Kicker 💜
Join Terri Conneran and Dr. Andrew Aguirre from Dana-Farber Cancer Institute as they dive into the latest breakthroughs in pancreatic cancer research.
From KRAS inhibitors and clinical trials to the growing role of immunotherapy, Dr. Aguirre shares what’s on the horizon — and what it means for patients and families facing KRAS cancers.
Whether you’re newly diagnosed, caregiving, or deep in the research world — this one’s packed with hope, knowledge, and real insight. 💪
Advances in Pancreatic Cancer Research: KRAS Inhibitors and Future Therapies with Dr. Andrew AguirreJoin Terri Conneran, Founder of KRAS Kickers and Dr. Andr...
Terri Conneran will moderate with cancer KOL's for the latest in KRAS Knowledge, Research, Advocacy & Survivorship.
10/27/2025
L I V E webinar see you soon!
bring questions!!
Andrew Aguirre, MD, PhD, is a medical oncologist at Dana-Farber Cancer Institute (DFCI), an Associate Professor of Medicine at Harvard Medical School, an Institute Member at the Broad Institute of Harvard and MIT, an Associate Director for the Hale Family Center for Pancreatic Cancer and a Co-Director of the Center for RAS Therapeutics at DFCI. Dr. Aguirre leads a basic and translational cancer research laboratory that studies pancreatic cancer biology and RAS signaling with the goal of developing new therapeutic strategies for patients.
You don’t want to miss this conversation with Dr. Andrew Aguirre, MD, PhD — a leading medical oncologist and researcher at Dana-Farber Cancer Institute. Dr. Aguirre is also an Associate Professor at Harvard Medical School and Co-Director of the Center for RAS Therapeutics at Dana-Farber.
10/07/2025
Exclusively for KRAS cancer patients and their care partners
Please join us for our next October 24 virtual support group to connect with others in a similar situation, we walk alongside of each other in our journey to kick cancer's KRAS!
She showed us that Survivorship isn’t only about years lived. It’s about walking through fear, lifting others as you go, and leaving every place you touch a little better than when you found it.That is Survivorship — and that is the legacy Bonnie gave us. Her hugs, her fire, her passion — th...
08/15/2025
Here’s a List of KRAS Trials We’re Sharing for Your Convenience
We put this together to try and help—because being informed matters. It’s not perfect or complete, just a good-faith courtesy post based on publicly available info.
Think of it as a starting point, not a guarantee. Please check with your health care team to see what may be right for you. Locally, a trial status may be different than what is reported.
We are the hub for all KRAS : Knowledge Research Advocacy Survivorship to kick cancer's KRAS~! KRAS is the most common cancer mutation. This NEW research can be life saving. Here is the current info as an easy resource for patients and care partners.
Once you know your options, the next question is: Am I eligible? Here’s how doctors typically determine if a patient qualifies for a clinical trial or specific therapy—regardless of cancer type. 6 things that matter...
..just been diagnosed—or are navigating next step—you’re not alone. Cancer care has changed dramatically in the last decade. Today, you may have more treatment choices than ever before. This post is designed to help you understand your options and feel confident asking the right questions.
Be the first to know and let us send you an email when KRAS Cancer Connect - KRAS Kickers posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
Going in for a second opinion right before my third ‘cancerversary’, I felt reasonably knowledgable about my stage IIIa non small cell lung cancer. Since my diagnosis, I have been through chemo, lobectomy, ablation and radiation accordingly the terminology was familiar. My tumor had undergone comprehensive biomarker mutation testing. While discussing next steps with the oncologist, rather flippantly, I said “It’s not like I have any bio-markers other than PD-L1..” Oh, but you do have kRas.
Wait, what ? KRAS ? How come I didn’t know? What do I need to know ? Where are the resources? Who is the KRAS organization of lung cancer warriors like EGFR, ALK & Ros1? Immediately, I reached out Go2Foundation, LUNGevity, Lung Cancer Foundation of America and LiveLUNG. It turns out, kRas cancer warriors need a community, an organization working to bring attention to the most common type of mutation within NSCLC. So here we are, ready to begin the challenge of kicking lung cancers kRas!!
kRasKickers.org is getting started. The vision is for patient driven, grassroots effort to share resources, experiences and encourage research. A single voice is easy to ignore, yet many voices together will be a chorus demanding attention. All lung cancer needs more treatments and a cure. KRas is a subgroup of lung cancer, we have different clinical trials, research and experiences to share and learn from each other.
If you don’t know your tumor mutations, ask your doctor. If you are KRAS, this is for us. Join the community of kRasKickers.org
